Compare Medpace Holdings Inc (MEDP) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs PepsiCo, Inc. — how do they compare? Medpace Holdings Inc trades at $530.31 (market cap $15.08B), while PepsiCo, Inc. trades at $134.4 (market cap $184.89B). The key difference: PepsiCo, Inc. is far larger — about 12.3× Medpace Holdings Inc's market cap, and PepsiCo, Inc. pays a 4.37% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | PEP | |
|---|---|---|
Market Cap | $15.08B | $184.89B |
Sector | Technology | Consumer Staples |
52-Week High | $620.59 | $170.44 |
52-Week Low | $308.88 | $135.40 |
Enterprise Value | $14.55B | $227.39B |
Dividend Yield | — | 4.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
PepsiCo (PEP) trades at $134.79, down 1.7% on the day, with a bearish technical signal and mixed fundamentals. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $2.20 surpassing the $2.19 estimate. Revenue growth remains steady, projected at $96.9B for 2026, though net margin dipped to 8.77% in 2025. The stock shows strong profitability metrics, including a 51.59% ROE, but faces headwinds from price sensitivity in its snack business, as highlighted by recent news of Doritos price cuts.
The outlook for PEP is cautiously optimistic, supported by analyst consensus and a $158.50 price target, implying 17.6% upside. Key opportunities include ongoing business transformation and dividend stability, while risks involve consumer pushback on pricing and competitive pressures. Institutional activity shows mixed signals, with some firms increasing stakes amid overall bearish technical trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
